

Ref: NSE/LIST/237462-M

April 30, 2014

The Company Secretary and Compliance Officer
Glenmark Pharmaceuticals Limited
Glenmark House, HDO Corporate Building,
Wing - A, B. D. Sawant Marg, Chakala,
Off Western Express Highway, Andheri – E,
Mumbai – 400099.

Kind Attn.: Mr. Sanjay Kumar Chowdhary

Dear Sir,

Sub: Observation letter for draft Scheme of Arrangement involving amalgamation of Glenmark Generics Limited and Glenmark Access Limited with Glenmark Pharmaceuticals Limited.

This has reference to draft Scheme of Arrangement involving amalgamation of Glenmark Generics Limited and Glenmark Access Limited with Glenmark Pharmaceuticals Limited submitted to NSE vide your letter dated February 12, 2014.

Based on our letter reference no Ref: NSE/LIST/233647-A submitted to SEBI and pursuant to SEBI Circular No. CIR/CFD/DIL/5/2013 dated February 04, 2013 and SEBI Circular no. CIR/CFD/DIL/8/2013 dated May 21, 2013, SEBI has vide letter dated April 30, 2014, has given following comments on the draft Scheme of Amalgamation:

“1. The company to ensure that additional information submitted with respect to pre-scheme and post-scheme shareholding is displayed from the date of receipt of this letter on the website of the listed company along with various documents submitted pursuant to the Circulars.

2. The company shall duly comply with various provisions of the Circulars.”

Accordingly, we do hereby convey our ‘No-objection’ with limited reference to those matters having a bearing on listing/ delisting/ continuous listing requirements within the provisions of the Listing Agreement, so as to enable the Companies to file the Scheme with Hon’ble High Court.

However, the Exchange reserves its rights to withdraw this No-objection approval at any stage if the information submitted to the Exchange is found to be incomplete/ incorrect/ misleading/ false or for any contravention of Rules, Bye-laws and Regulations of the Exchange, Listing Agreement, Guidelines / Regulations issued by statutory authorities.

The validity of this “Observation Letter” shall be six months from April 30, 2014, within which the Scheme shall be submitted to the Hon’ble High Court. Further pursuant to the above SEBI circulars upon sanction of the Scheme by the Hon’ble High Court, you shall submit to NSE the following:



Ref: NSE/LIST/237462-M

April 30, 2014

- a. Copy of Scheme as approved by the High Court;
- b. Result of voting by shareholders for approving the Scheme;
- c. Statement explaining changes, if any, and reasons for such changes carried out in the Approved Scheme vis-à-vis the Draft Scheme
- d. Status of compliance with the Observation Letter/s of the stock exchanges
- e. The application seeking exemption from Rule 19(2)(b) of SCRR, 1957, wherever applicable; and
- f. Complaints Report as per Annexure II of SEBI Circular No. CIR/CFD/DIL/5/2013 dated February 4, 2013.

Yours faithfully,
For National Stock Exchange of India Limited

Kamlesh Patel
Manager

P.S. Checklist for all the Further Issues is available on website of the exchange at the following URL
http://www.nseindia.com/corporates/content/further_issues.htm
